U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H23NO3
Molecular Weight 325.4015
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORM-12741

SMILES

OC1=CC=CC(=C1)[C@H]2CCCN(C[C@H]3COC4=CC=CC=C4O3)C2

InChI

InChIKey=FOESNAGBEJURCI-WMZOPIPTSA-N
InChI=1S/C20H23NO3/c22-17-7-3-5-15(11-17)16-6-4-10-21(12-16)13-18-14-23-19-8-1-2-9-20(19)24-18/h1-3,5,7-9,11,16,18,22H,4,6,10,12-14H2/t16-,18-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637

Juvantia Pharma and Orion developed ORM-12741, also known as ORM-10921, a novel selective antagonist of alpha-2C adrenoceptors for the treatment of depression and Alzheimer's disease. ORM-12741 participated in phase II clinical trial where was evaluated the safety and efficacy of the drug in patients with Alzheimer's disease. In spite of the successfully completed phase II, further study of the drug for this disease was discontinued. In addition, ORM-12741 participated in clinical trial phase II to prove the concept that this drug could prevent blood vessel spasms for Raynaud's phenomenon. Raynaud's phenomenon is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. However, this study was terminated because of the recommendation by study Data and Safety Monitoring Committee to the sponsor following the interim analysis of 8 subjects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis.
2007 Nov 1
Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.
2017 Jan
Patents

Patents

Sample Use Guides

Name Type Language
ORM-12741
Code English
DB-105
Code English
Phenol, 3-[(3R)-1-[[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-3-piperidinyl]-
Systematic Name English
3-[(3R)-1-[[(2S)-2,3-Dihydro-1,4-benzodioxin-2-yl]methyl]-3-piperidinyl]phenol
Systematic Name English
Code System Code Type Description
SMS_ID
100000184092
Created by admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
PRIMARY
DRUG BANK
DB12057
Created by admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
PRIMARY
CAS
1106938-11-7
Created by admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
PUBCHEM
25175001
Created by admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
PRIMARY
FDA UNII
D26C95A960
Created by admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
PRIMARY